Meelan Bul1, Nicolas B. Delongchamps2, Ewout W. Steyerberg3, Gustavo de la Roza4, Pim J. van Leeuwen1, Xiaoye Zhu1, Heidi A. van Vugt1, Gabriel P. Haas5, Fritz H. Schröder1, Monique J. Roobol1
Canadian Journal of Urology, Vol.18, No.2, pp. 5625-5629, 2011
Abstract Introduction and objective: The Prostate Cancer Risk Indicator is a validated tool used to predict the likelihood that a screen-detected prostate cancer is indolent, partially based on lateralized sextant biopsies. Our objective was to derive correction factors for updating this model to reflect contemporary extended biopsy schemes.
Materials and methods: Post-mortem 18-core biopsy results from men who died of unrelated causes but were diagnosed with prostate cancer post-mortem were analyzed. These data included details from both biopsy samples and whole-mount pathological specimens. For each positive 18-core biopsy, the Gleason score, number of positive cores, tumor location within the… More >